Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

por Wang, Rong, Yang, Yuchen, Ye, Wei-Wu, Xiang, Jianxing, Chen, Songan, Zou, Wei-Bin, Wang, Xiao-Jia, Chen, Tianhui, Cao, Wen-Ming
Publicado 2021